Bassline Productions

Bassline Productions is an OTC-traded microcap company associated historically with immunotherapeutic development centered on irreversible pepsin fraction (IPF), a protein-based platform described for cancer, autoimmune disease, cirrhosis, and hepatitis C applications. The company was originally formed for non-healthcare activities and later became tied to development-stage biotech assets through transactions involving Reve Technologies and Canteck/Cantech Pharma. More recent OTC disclosure indicates that, as of 2021, the company was seeking a merger or acquisition candidate and working to become current, while a prior agreement related to Canteck Pharma technology had been rescinded. As a result, Bassline Productions appears better characterized today as a dormant or shell-like public company with historical biotech positioning rather than an operating clinical-stage biotech with an active disclosed pipeline.